Why most randomized phase II cervical cancer chemoprevention trials are uninformative: Lessons for the future

Journal of the National Cancer Institute

Volumn 93, Issue 17, 2001, Pages 1293-1296

  Follen, Michele ^a   Meyskens Jr , Frank L ^b   Atkinson, E Neely ^a   Schottenfeld, David ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; BIOCHEMICAL MARKER; EFLORNITHINE; FOLIC ACID; PHOSPHATIDYLCHOLINE; PLACEBO; RETINOIC ACID; RETINOID DERIVATIVE; TRACE ELEMENT;

CANCER GRADING; CANCER REGRESSION; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL STUDY; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; LASER SURGERY; METHODOLOGY; NOTE; PAPANICOLAOU TEST; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SAMPLE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0035812290     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.17.1293     Document Type: Note

References (27)

1. Estimates of the worldwide incidence of 25 major cancers in 1990
2. A clinical trial using 4-hydroxyphenylretinamide for the treatment of high-grade squamous intraepithelial lesions of the cervix: An interim analysis
3. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial
4. Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection
5. Effects of β-carotene on cervical intraepithelial neoplasia: Six-month interim results of a two-year phase II/III trial
6. The effect of beta-carotene on the regression and progression of cervical dysplasia: A clinical experiment
7. A randomized clinical trial of beta carotene vs placebo for the treatment of cervical HPV infection
8. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities
9. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives
10. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial
11. Chemoprevention of cervical cancer with folic acid: A phase II Southwest Oncology Group Intergroup study
12. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
13. Chemoprevention trials in the cervix: Design, feasibility, and recruitment
14. Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy
15. The natural history of cervical intraepithelial neoplasia: An argument for intermediate endpoint biomarkers
16. Natural history of cervical intraepithelial neoplasia: A critical review
17. Meta-analysis of Pap test accuracy
18. Screening for squamous intraepithelial lesions with fluorescence spectroscopy
19. Fluorescence spectroscopy for diagnosis of squamous intraepithelial lesions of the cervix
20. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for the treatment of squamous intraepithelial lesions of the cervix
21. Preinvasive diseases of the female lower genital tract
22. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
23. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV 16) transgenic mice
24. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials
25. The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives